CDEX Inc. Appoints Dr. Jason B. Terrell as Medical Director
Published: Jan 26, 2012
TUCSON, AZ--(Marketwire - January 26, 2012) - CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products using patented technologies for use in healthcare, safety and security markets, today announced the appointment of Jason Bradley Terrell, M.D. as medical director of the company. Dr. Terrell will be responsible for CDEX's research and development, as well as regulatory and medical affairs related to the launch and ongoing development of the Valimed G4 drug validation system.
Jeff Brumfield, chairman and chief executive officer of CDEX, stated, "We are very pleased to welcome Dr. Terrell to our team. He brings to CDEX a unique blend of medical science expertise and progressive medical field business operations background. He will assist in the market application and implementation of CDEX technologies in the medical field and advise on the ongoing development to address other unique unmet needs where the VG4 may be instrumental in detecting foreign related substances."
Dr. Terrell is currently a corporate medical director for Any Lab Test Now©, the largest direct access medical testing franchise in the United States. Dr. Terrell currently owns and operates multiple medical laboratory testing facilities in the Southwest United States. He earned his Bachelor of Science in Biochemistry from Hardin-Simmons University, graduating Summa Cum Laude and recipient of the Holland Medal of Honor. He earned his MD from the University of Texas at Houston School of Medicine.
"I am excited to join the outstanding team at CDEX. The technology promises to have a global impact in multiple industries. I believe the Valimed G4 will revolutionize parenteral medication safety practices and narcotic diversion control in both healthcare and closely related industries," stated Jason B. Terrell, M.D., medical director of CDEX. "What's really exciting is that CDEX's patented technology can be applied to the analysis of blood, urine, saliva, and other bodily fluids. Preliminary data suggests that the technology provides many advantages over current diagnostics techniques, including the ability to detect lower molecular concentrations, increased sensitivity and specificity with real-time analysis. One of my goals as medical director is to facilitate additional research studies and trials in these areas to expand future product use."
CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.
Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.